argenex SE $ARGX Shares Sold by Iron Triangle Partners LP

Iron Triangle Partners LP decreased its holdings in shares of argenex SE (NASDAQ:ARGX) by 36.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,900 shares of the company’s stock after selling 5,667 shares during the quarter. argenex makes up approximately 1.0% of Iron Triangle Partners LP’s holdings, making the stock its 25th biggest holding. Iron Triangle Partners LP’s holdings in argenex were worth $7,302,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Capital World Investors grew its stake in argenex by 0.4% during the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock worth $1,445,113,000 after buying an additional 8,422 shares during the last quarter. Wellington Management Group LLP grew its position in shares of argenex by 80.1% during the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after acquiring an additional 324,653 shares during the last quarter. Bank of America Corp DE grew its position in shares of argenex by 1.9% during the third quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock worth $252,525,000 after acquiring an additional 6,259 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of argenex by 114.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock worth $163,775,000 after acquiring an additional 158,476 shares during the period. Finally, Two Sigma Investments LP boosted its stake in argenex by 570.3% during the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock valued at $216,961,000 after purchasing an additional 250,278 shares during the period. Institutional investors own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ARGX shares. DZ Bank raised argenex to a “strong-buy” rating in a report on Friday, December 19th. Guggenheim lowered their target price on argenex from $1,160.00 to $1,120.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Wall Street Zen downgraded argenex from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Zacks Research upgraded argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Finally, Morgan Stanley increased their price target on argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a research note on Thursday, December 4th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, argenex currently has a consensus rating of “Moderate Buy” and an average price target of $999.22.

argenex Stock Down 1.2%

ARGX opened at $700.45 on Monday. The business has a fifty day simple moving average of $804.00 and a 200-day simple moving average of $817.49. The firm has a market cap of $43.34 billion, a PE ratio of 35.88, a P/E/G ratio of 1.16 and a beta of 0.38. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62.

argenex (NASDAQ:ARGX) last released its earnings results on Thursday, February 26th. The company reported $8.02 earnings per share for the quarter, topping the consensus estimate of $6.05 by $1.97. The business had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. argenex had a net margin of 30.42% and a return on equity of 38.51%. On average, equities research analysts anticipate that argenex SE will post 3.13 EPS for the current fiscal year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.